for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Corbus Pharmaceuticals Holdings Inc

CRBP.OQ

Latest Trade

5.26USD

Change

-0.22(-4.01%)

Volume

355,466

Today's Range

5.25

 - 

5.57

52 Week Range

4.98

 - 

9.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.48
Open
5.48
Volume
355,466
3M AVG Volume
12.99
Today's High
5.57
Today's Low
5.25
52 Week High
9.11
52 Week Low
4.98
Shares Out (MIL)
64.65
Market Cap (MIL)
340.07
Forward P/E
-4.64
Dividend (Yield %)
--

Latest Developments

More

Corbus Pharmaceuticals Q2 Earnings Per Share $0.03

Corbus Pharmaceuticals Reports Q1 2019 Results

Corbus Pharma Announces Change Of Primary Endpoint In Ongoing Phase 3 Study In Systemic Sclerosis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Industry

Biotechnology & Drugs

Contact Info

100 River Ridge Dr

+1.617.9630103

https://www.corbuspharma.com/

Executive Leadership

Yuval Cohen

Chief Executive Officer, Director

Sean F. Moran

Chief Financial Officer

Robert Paul Discordia

Vice President, Pharmaceutical Development & Manufacturing

Sergei Atamas

Executive Director - Research

Craig Stuart Millian

Chief Commercial Officer

Key Stats

1.71 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.490

2017

-0.650

2018

-0.980

2019(E)

-1.142
Price To Earnings (TTM)
--
Price To Sales (TTM)
10.00
Price To Book (MRQ)
7.18
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.21
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-100.41
Return on Equity (TTM)
-72.52

Latest News

BRIEF-Corbus Pharmaceuticals Reports Q1 Loss Per Share $0.21

* CORBUS PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Corbus Pharmaceuticals Reports 2017 Financial Results And Provides Clinical Update

* CORBUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE

BRIEF-Corbus Pharmaceuticals Receives $25 Mln Development Award From The Cystic Fibrosis Foundation

* CORBUS PHARMACEUTICALS RECEIVES $25 MILLION DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION TO SUPPORT PHASE 2B CLINICAL STUDY OF LENABASUM Source text for Eikon: Further company coverage:

BRIEF-Corbus Agrees With FDA On Phase 2B Cystic Fibrosis Study Design With Pulmonary Exacerbations As Sole Primary Endpoint

* CORBUS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH FDA ON PHASE 2B CYSTIC FIBROSIS STUDY DESIGN WITH PULMONARY EXACERBATIONS AS SOLE PRIMARY ENDPOINT

Corbus cystic fibrosis drug to get FDA review on flare-up data

Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop...

BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln

* CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2EciBBu) Further company coverage:

BRIEF-Corbus Pharma Initiates Phase 2 Study Of Anabasum For Treatment Of Systemic Lupus Erythematosus

* CORBUS PHARMACEUTICALS ANNOUNCES INITIATION OF PHASE 2 STUDY OF ANABASUM FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS Source text for Eikon: Further company coverage:

BRIEF-Corbus Pharmaceuticals Q3 loss per share $0.14

* Corbus Pharmaceuticals reports 2017 third quarter financial results and highlights recent corporate and clinical advancements

BRIEF-Corbus Pharma reports improvement in skin conditions in a mid-stage study

* Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study

BRIEF-Corbus Pharma prices underwritten public offering of common stock

* Corbus Pharmaceuticals Holdings, Inc. prices underwritten public offering of common stock

BRIEF-Corbus Pharmaceuticals Holdings announces proposed public offering of common stock

* Corbus Pharmaceuticals Holdings Inc announces proposed public offering of common stock

BRIEF-Corbus Pharma's inflammatory disease drug succeeds mid-stage study

* Corbus Pharmaceuticals reports positive topline results from phase 2 study in rare autoimmune disease dermatomyositis

BRIEF-Corbus Pharmaceuticals Holdings reports Q2 loss per share $0.15

* Corbus Pharmaceuticals reports 2017 second quarter financial results and provides business update

BRIEF-Corbus Pharmaceuticals presented data from phase 2 study of anabasum for treatment of systemic sclerosis

* Corbus Pharmaceuticals presented data from phase 2 study of anabasum for the treatment of systemic sclerosis at the eular 2017 annual meeting

BRIEF-Corbus announces last subject enrolled in Phase 2 study of anabasum

* Corbus pharmaceuticals announces last subject enrolled in phase 2 study of anabasum for the treatment of skin-predominant dermatomyositis

BRIEF-Corbus Pharmaceuticals Q1 loss per share $0.16

* Corbus Pharmaceuticals reports 2017 first quarter financial results and provides business update

Corbus Pharma outlines U.S. approval path for lead drug

The U.S. Food and Drug Administration needs Corbus Pharmaceuticals to show positive data from only one late-stage study on its experimental treatment for scleroderma to support a marketing application, the company said.

Corbus Pharma outlines U.S. approval path for lead drug

The U.S. Food and Drug Administration needs Corbus Pharmaceuticals to show positive data from only one late-stage study on its experimental treatment for scleroderma to support a marketing application, the company said.

BRIEF-Corbus Pharma outlines U.S. approval path for anabasum

* Corbus Pharmaceuticals to commence single Phase 3 study of anabasum for treatment of systemic sclerosis after guidance from end-of-phase 2 meeting with FDA

Corbus outlines U.S. approval path for lead drug

Corbus Pharmaceuticals said on Wednesday that the U.S. health regulator only requires one positive pivotal late-stage study to support a marketing application for its lead experimental therapy as a treatment for scleroderma.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up